Is Mar­tin Shkre­li blog­ging from prison?

Say what you will about Mar­tin Shkre­li, but the guy ap­pears to have a re­lent­less re­silience to be heard. A few months in­to his prison sen­tence at Fort Dix, Shkre­li might be blog­ging from his cell.

That’s ac­cord­ing to ac­tiv­i­ty on this site — mar­tin­shkre­li.com — which saw its first en­try post­ed yes­ter­day. Al­though it’s still un­clear if the blog is gen­uine, the first post was writ­ten in Shkre­li’s now-fa­mil­iar wry voice and style. He shares his per­son­al con­tact in­for­ma­tion, in­clud­ing an email ad­dress you can send ques­tions to. His peo­ple will print the emails and “snail mail” them to Shkre­li at the cor­rec­tion­al fa­cil­i­ty, the post says.

I’ve reached out to Fort Dix, the prison where Shkre­li is cur­rent­ly serv­ing his 7-year sen­tence for se­cu­ri­ties fraud, to see if Shkre­li can ac­tu­al­ly post blogs while in­car­cer­at­ed. What ac­cess does he have to the in­ter­net? In what cir­cum­stances would the fa­cil­i­ty in­ter­fere with his blog­ging? The in­sti­tu­tion took my call, but said it need­ed time to re­spond. I’m still wait­ing to hear back.

If the blog is in­deed gen­uine, it seems Shkre­li is de­ter­mined to share his thoughts on in­dus­try mat­ters. The first sec­tion of his first en­try is com­men­tary on bio stocks and in­dus­try news, with mus­ings like the one be­low:

No­var­tis’ much-telegraphed sale of Al­con and the con­tin­ued im­plo­sion of GE re­minds us con­glom­er­ates are more out of fash­ion than prob­a­bly at any point in the his­to­ry of busi­ness. This flies in the face of me­chan­i­cal log­ic, but prac­ti­cal­ly makes sense. Find­ing good man­agers is hard (I’ve maybe found a very small hand­ful of de­cent man­agers out of close to 1000 I’ve em­ployed over the years) and con­glom­er­ates can on­ly work if you have an en­gaged CEO (about 5% of CEOs) and en­gaged man­agers (less than 5%? less than 10%?), which prob­a­bil­i­ty tells you is far low­er.

Then he out­lines sci­en­tif­ic pa­pers he’s read from prison and adds notes on what he thinks about each. Last, he ded­i­cates a few para­graphs to his per­son­al life.

“I have around 38 months to go as­sum­ing no suc­cess on an ap­peal,” he wrote. “I spend most of my team [sic] read­ing. A news­pa­per mis­re­port­ed that I’m ‘buff’. This is not the case.”

He al­so writes that news out­lets have mis­re­port­ed facts about his as­sets.

“Oh, the Wu-Tang al­bum is still in my pos­ses­sion,” he wrote. “As are all of my as­sets.”

News writ­ers re­port­ed back in March that US Dis­trict Judge Kiyo Mat­sumo­to or­dered Shkre­li to for­feit $7.36 mil­lion. But that or­der got stayed — as we re­port­ed — pend­ing Shkre­li’s ap­peal, which could take a year or so to wrap up.

The news of Shkre­li’s blog was first not­ed by Christie Smythe, a le­gal jour­nal­ist who’s writ­ing a book about Shkre­li. Fol­low the con­ver­sa­tion via this tweet, and we’ll up­date this sto­ry once Fort Dix gets back to us:


Im­age: Mar­tin Shkre­li. SHUT­TER­STOCK

Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED #ES­MO20: Trodelvy da­ta show that Gilead­'s $21B buy­out may have been worth the big pre­mi­um

Gilead CEO Dan O’Day has been on a shopping spree. And while some analysts gawked at the biotech’s recent $21 billion Immunomedics buyout, new data released at virtual ESMO 2020 suggest the acquisition may have been worth the hefty price.

The deal, announced last weekend, will give California-based Gilead $GILD Trodelvy, which was recently approved for metastatic triple-negative breast cancer (mTNBC).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: As­traZeneca bur­nish­es Tagris­so's ad­ju­vant NSCLC pro­file with 'un­prece­dent­ed' re­duc­tion in brain mets. Can they win over skep­tics?

When AstraZeneca trumpeted “momentous” and “transformative” results for Tagrisso earlier this year at ASCO, some practitioners threw cold water on the ADAURA fervor. Sure, the disease-free survival data look good, but overall survival is the endpoint that matters when it comes to choosing adjuvant therapy for non-small cell lung cancer patients, the experts said.

The OS data still aren’t here, but AstraZeneca is back at ESMO to bolster their case with a look at brain metastasis data.

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

Rep. Andy Harris (R-MD) (Tasos Katopodis/Pool via AP Images)

UP­DAT­ED: A mi­cro-cap with a po­ten­tial­ly promis­ing coro­n­avirus drug en­lists mask-skep­tic con­gress­man for DSMB

A small biotech that has talked up a potentially promising but unproven treatment for Covid-19 enlisted an unusual member for its study’s Data and Safety Monitoring Board: a sitting Republican congressman with close ties to the CEO and a history of mask skepticism.

NeuroRx, an Israeli biotech testing a lung inflammation drug in Covid-19 patients, tapped Maryland Rep. Andy Harris for the DSMB, Politico reported. Harris is an anesthesiologist but not a biostatistician, and he has questioned the CDC about a “cult of masks” in the US. Harris has known NeuroRx CEO Jonathan Javitt since the two worked at Johns Hopkins together over 20 years ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Alk­er­mes of­fers their first snap­shot of a ben­e­fit for their next-gen IL-2 drug. But why did 1 pa­tient starve to death?

Everyone in the cancer R&D arena is looking to build new franchises around better drugs and combos. And one busy pocket of that space is centered entirely on creating an IL-2 drug that can be as effective as the original without the toxicity that damned it to the sidelines.

Alkermes $ALKS formally tossed its hat into the ring of contenders at virtual ESMO today, highlighting the first glimpse of efficacy for their candidate, ALKS 4230, as both a monotherapy as well as in combination with Merck’s Keytruda.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Albert Bourla (Photo by Steven Ferdman/Getty Images)

Pfiz­er match­es Mod­er­na with their full Covid-19 tri­al blue­print — As­traZeneca says it will un­veil its pro­to­col 'short­ly'

Yesterday, after sustained public pressure as Moderna released its Phase III Covid-19 trial blueprint, Pfizer released its own full trial design for their vaccine trials. The move was designed to boost transparency and shore up public trust in the vaccines, but it also revealed differences in how the two companies are approaching the much-watched studies while failing to satisfy the demands of the fiercest advocates for transparency.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Stronger to­geth­er? Boehringer and Mi­rati team to put first KRAS-KRAS com­bo in the clin­ic

Researchers are still waiting to see how much any of the vaunted KRAS drugs now in the clinic can, after decades of preclinical research and some early human studies, help patients. But while they do, two of the leading developers will look to see whether a KRAS-KRAS combo might pose a better shot than any KRAS alone.

Boehringer Ingelheim and Mirati have signed a collaboration to combine Mirati’s closely-watched lead KRAS inhibitor, MRTX849, in a clinical trial with the pan-KRAS blocker that Boehringer has quietly developed with high expectations behind their flashier contenders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.